- Keros Therapeutics (KROS +5.9%) has dosed the first two participants in a Phase 2 clinical trial evaluating KER-050 for the treatment of anemia and thrombocytopenia in myelodysplastic syndromes (MDS).
- Keros presented data from its Phase 1 clinical trial of KER-050 in healthy post-menopausal women at the 25th Annual Congress of European Hematology Association in June 2020.
- The Phase 2 clinical trial will be carried in 2 parts, Part 1 will enroll ~6 participants in each up to four cohorts of ascending doses of KER-050 for four weeks up to four cycles. Part 2, the dose selected from Part 1 will be evaluated in up to 30 participants.
- The primary objective are safety in MDS participants with ring sideroblasts as well as in participants without ring sideroblasts.
- Keros expects to report initial data from Part 1 of this trial in mid-2021.
- MDS is considered a type of cancer and occur when the blood-forming cells in the bone marrow become abnormal. This leads to low numbers of one or more types of blood cells.